NCT06967207 Electrical Impedance Tomography-Based Prognostic Model for ARDS
| NCT ID | NCT06967207 |
| Status | Recruiting |
| Phase | — |
| Sponsor | XiaoJing Zou,MD |
| Condition | Acute Respiratory Distress Syndrome (ARDS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 625 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 625 participants in total. It began in 2025-04-15 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter, prospective, observational study aims to develop and validate an EIT-based prognostic model for ARDS. By focusing on the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury, the investigators intend to establish a prognostic model that reveals lung injury and heterogeneity, enabling risk stratification and guiding individualized treatment.
Eligibility Criteria
Inclusion Criteria: 1. Meet the new 2023 ARDS global definition; 2. Age 18-80 years Exclusion Criteria: 1. Expected death within 24 hours of screening; 2. Metastatic cancer (active malignancy with distant metastases); 3. Severe psychiatric disorders; 4. Pregnancy or postpartum status; 5. Pneumothorax or moderate to large pleural effusion without adequate drainage; 6. Chronic respiratory failure; 7. Patients with pulmonary embolism or pulmonary hypertension; 8. Heart failure patients: EF \<50% or NYHA class III or IV; 9. Patient/family refusal to participate; 10. Participation in another interventional trial within 3 months prior to enrollment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06967207 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Acute Respiratory Distress Syndrome (ARDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06967207 currently recruiting?
Yes, NCT06967207 is actively recruiting participants. Contact the research team at 249126734@qq.com for enrollment information.
Where is the NCT06967207 trial being conducted?
This trial is being conducted at Guangzhou, China, Wuhan, China, Wuhan, China, Shanghai, China.
Who is sponsoring the NCT06967207 clinical trial?
NCT06967207 is sponsored by XiaoJing Zou,MD. The trial plans to enroll 625 participants.